Clinical Validation of a Urine-based Assay With Genomic and Epigenomic Markers for Predicting Recurrence During Surveillance for Non-muscle Invasive Bladder Cancer
Clint Cary, MD
Primary Investigator
Overview
A study to validate, in a prospective manner, the ability of the predefined Genomic Health bladder cancer assay to detect recurrence in patients undergoing surveillance for non-muscle invasive bladder cancer.
Description
A study to validate, in a prospective manner, the ability of the predefined Genomic Health bladder cancer assay to detect recurrence in patients undergoing surveillance for non-muscle invasive bladder cancer.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
bladder cancer
-
Age: Between 18 Years - 80 Years
-
Gender: All
Inclusion Criteria
Patients with a prior diagnosis of non-muscle invasive, <=T1, urothelial cell carcinoma of the bladder scheduled to undergo surveillance cystoscopy.
Exclusion Criteria
Patients with a diagnosis of small cell carcinoma, adenocarcinoma or squamous cell carcinoma of the bladder
Patients who have had a cystectomy or prior diagnosis of muscle invasive disease (T2 or greater)
